SG11201900814QA - Viral vaccines - Google Patents

Viral vaccines

Info

Publication number
SG11201900814QA
SG11201900814QA SG11201900814QA SG11201900814QA SG11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA SG 11201900814Q A SG11201900814Q A SG 11201900814QA
Authority
SG
Singapore
Prior art keywords
international
victoria
pct
chikungunya
zika virus
Prior art date
Application number
SG11201900814QA
Other languages
English (en)
Inventor
Paul Howley
Original Assignee
Sementis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by Sementis Ltd filed Critical Sementis Ltd
Publication of SG11201900814QA publication Critical patent/SG11201900814QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201900814QA 2016-08-19 2017-08-18 Viral vaccines SG11201900814QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
PCT/AU2017/050879 WO2018032057A1 (fr) 2016-08-19 2017-08-18 Vaccins contre des virus

Publications (1)

Publication Number Publication Date
SG11201900814QA true SG11201900814QA (en) 2019-03-28

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900814QA SG11201900814QA (en) 2016-08-19 2017-08-18 Viral vaccines

Country Status (17)

Country Link
US (2) US10905759B2 (fr)
EP (2) EP3500280A4 (fr)
JP (1) JP2019528271A (fr)
KR (1) KR20190050787A (fr)
CN (1) CN109862909A (fr)
AR (1) AR110624A1 (fr)
AU (1) AU2017313450B2 (fr)
BR (1) BR112019003181A2 (fr)
CA (1) CA3034282A1 (fr)
CL (1) CL2019000405A1 (fr)
IL (1) IL264893B (fr)
MA (1) MA45994A (fr)
MX (1) MX2019001919A (fr)
NZ (1) NZ750578A (fr)
SG (1) SG11201900814QA (fr)
TW (1) TWI728173B (fr)
WO (1) WO2018032057A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3911010B2 (ja) * 1994-04-29 2007-05-09 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
CN1418951A (zh) 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
WO2003097846A1 (fr) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Poxvirus recombinant exprimant des genes homologues introduits dans le genome poxviral
EP2269619A1 (fr) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Procédés et compositions concernant des poxvirus et le cancer
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
DK1594970T3 (da) * 2003-02-18 2008-11-17 Helmholtz Zentrum Muenchen Fremgangsmåde til generering af rekombinant MVA
EP1518932A1 (fr) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Mutant du virus de la vaccine Ankara modifié (MVA) et utilisation correspondante
EP1683870A1 (fr) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccins à base de l'utilisation de MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2618840A2 (fr) * 2010-09-23 2013-07-31 Baxter International Inc. Vecteurs viraux recombinants et procédés d'induction d'une réponse immunitaire vis-à-vis du virus de la fièvre jaune
CN105163756A (zh) * 2013-03-15 2015-12-16 赛门蒂斯有限公司 免疫调节
CN106255758B (zh) * 2013-11-01 2020-06-23 赛门蒂斯有限公司 病毒载体制造
WO2016086980A1 (fr) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Composition de vaccin
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus

Also Published As

Publication number Publication date
AU2017313450B2 (en) 2024-02-15
MX2019001919A (es) 2019-09-04
BR112019003181A2 (pt) 2019-07-16
TW201809273A (zh) 2018-03-16
IL264893A (fr) 2019-04-30
NZ750578A (en) 2023-05-26
TWI728173B (zh) 2021-05-21
WO2018032057A1 (fr) 2018-02-22
AU2017313450A1 (en) 2019-02-28
CN109862909A (zh) 2019-06-07
IL264893B (en) 2022-08-01
CL2019000405A1 (es) 2019-06-14
KR20190050787A (ko) 2019-05-13
CA3034282A1 (fr) 2018-02-22
EP4331676A3 (fr) 2024-05-15
JP2019528271A (ja) 2019-10-10
EP4331676A2 (fr) 2024-03-06
US20210113684A1 (en) 2021-04-22
US10905759B2 (en) 2021-02-02
US20200009245A1 (en) 2020-01-09
RU2019107582A (ru) 2020-09-21
MA45994A (fr) 2021-03-17
AR110624A1 (es) 2019-04-17
EP3500280A4 (fr) 2020-05-13
EP3500280A1 (fr) 2019-06-26
RU2019107582A3 (fr) 2021-03-31

Similar Documents

Publication Publication Date Title
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811432WA (en) Rna for cancer therapy
SG11201805120YA (en) Zika virus vaccine
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811600PA (en) Pseudotyped oncolytic viral delivery of therapeutic polypeptides
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201805835WA (en) Modified oncolytic virus
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201811370XA (en) A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201903042VA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201808709VA (en) T cell receptors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201803951QA (en) Oligonucleotides for inducing paternal ube3a expression
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11202000312UA (en) Encapsulated polynucleotides and methods of use